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Up to 60% of U.S. visitors to Mexico develop traveler’s diarrhea (TD), mostly due to enterotoxigenic
Escherichia coli (ETEC) strains that produce heat-labile (LT) and/or heat-stable (ST) enterotoxins.
Distinct single-nucleotide polymorphisms (SNPs) within the interleukin-10 (IL-10) promoter have been
associated with high, intermediate, or low production of IL-10. We conducted a prospective study to
investigate the association of SNPs in the IL-10 promoter and the occurrence of TD in ETEC LT-exposed
travelers. Sera from U.S. travelers to Mexico collected on arrival and departure were studied for ETEC LT
seroconversion by using cholera toxin as the antigen. Pyrosequencing was performed to genotype IL-10
SNPs. Stools from subjects who developed diarrhea were also studied for other enteropathogens. One
hundred twenty-one of 569 (21.3%) travelers seroconverted to ETEC LT, and among them 75 (62%)
developed diarrhea. Symptomatic seroconversion was more commonly seen in subjects who carried a
genotype producing high levels of IL-10; it was seen in 83% of subjects with the GG genotype versus 54%
of subjects with the AA genotype at IL-10 gene position 1082 (P, 0.02), in 71% of those with the CC
genotype versus 33% of those with the TT genotype at position 819 (P, 0.005), and in 71% of those with
the CC genotype versus 38% of those with the AA genotype at position 592 (P, 0.02). Travelers with the
GCC haplotype were more likely to have symptomatic seroconversion than those with the ATA haplotype
(71% versus 38%; P, 0.002). Travelers genetically predisposed to produce high levels of IL-10 were more
likely to experience symptomatic ETEC TD.
Traveler’s diarrhea (TD) affects up to 60% of short-term
U.S. visitors to developing countries (23). Although TD is a
self-limited disease with few acute complications, it can result
in significant transient discomfort, cause changes in travel
plans, and produce temporary incapacitation (25). TD has also
been associated with long-term complications, such as postin-
fectious reactive arthritis, (27) Guillain-Barre´ neuropathy (22),
and postinfectious irritable bowel syndrome (17).
Up to 85% of TD cases are bacterial in origin. In Mexico,
enterotoxigenic Escherichia coli (ETEC) is the single most-
commonly identified agent in the stools of travelers with diar-
rhea, ranging from 19% to 40% of cases (3). ETEC isolates
from travelers can produce heat-labile toxin (LT), heat-stable
toxin (ST), or both toxins simultaneously (LT/ST). Approxi-
mately 43% to 68% of strains isolated from subjects with TD in
Mexico produce LT alone or in combination with ST (1, 11,
13). Contact with ETEC LT, as a result of vaccination or after
natural infection, is associated with the production of LT-
specific antibodies (8, 15) and may serve as an indicator of
ETEC LT exposure.
Previous studies carried out in Bangladesh have demon-
strated that after adjusting for confounding variables, such as
age and prior exposure, ETEC LT can be identified with sim-
ilar frequencies in the stools of children with diarrhea and
healthy controls (7) and that the rates of seroconversion to
ETEC LT are similar in children with diarrhea and healthy
controls (18). This suggests that the variability in clinical out-
comes does not depend only on acquired immunity and in-
volves other factors related to the pathogen or host. Implicated
pathogen factors include bacterial load, presence of coloniza-
tion factors, other virulence determinants, the efficiency of LT
production, and coinfection with other pathogens. Variabil-
ity in susceptibility may also be determined by host factors,
such as the presence of host receptors for the pathogen,
genetic variability in other molecules that mediate susceptibility,
response to injury, and control and clearance of ETEC LT.
Interleukin-10 (IL-10) is an anti-inflammatory cytokine pro-
duced by dendritic cells, macrophages, and T-helper (Th) lym-
phocytes that downregulates the production of inflammatory
mediators (26). Three major single-nucleotide polymorphisms
(SNPs) in the promoter region of the IL-10 gene (1082 G/A,
819 C/T, and592 C/A) determine the level of production of
IL-10; the resulting GCC allele has been associated with high
IL-10 production, whereas the ATA allele has been associated
with low IL-10 production. Polymorphisms in the IL-10 gene
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have been shown to affect the risk for septic shock and its
outcomes (21), the incidence of invasive aspergillosis (20), the
progression of hepatitis B (6), and paracoccidioidomycosis (4),
among other infections.
In a previous study, we observed high levels of IL-10 in the
stools obtained from travelers with diarrhea who were coin-
fected with ETEC and norovirus, but not in the stools of
travelers for whom norovirus was identified as a single patho-
gen or who had pathogen-negative diarrhea (14). We hypoth-
esized that in U.S. travelers visiting Mexico and as seen in
other infections, genetic variations in the production of IL-10
could play a role in determining the outcome of ETEC infec-
tion (16). In this prospective observational cohort study, we
examined the influence that SNPs in the IL-10 gene have on
the incidence of ETEC LT-associated infection as determined
by ETEC-specific seroconversion in U.S. travelers who made
short-term visits to Mexico.
MATERIALS AND METHODS
Enrollment and surveillance. The study was conducted in two language
schools in Cuernavaca, Mexico, during the summer months of 2005 and 2006.
Travelers with a length of stay of between 11 and 48 days were included in this
study. Exclusion criteria precluding participation were: (i) antibiotic use within
the previous 2 weeks; (ii) use of antacids, H2 blockers, or proton pump inhibitors;
(iii) use of probiotics; (iv) history of significant underlying enteric, pulmonary,
cardiac, or renal disease; (v) seizure disorder; (vi) insulin-dependent diabetes;
(vii) human immunodeficiency virus infection or immunosuppressive therapy;
(viii) known history of lactose intolerance; and (ix) cholera vaccination in the
past 2 years.
Total blood for DNA extraction was collected from the individuals on arrival,
and a serum sample was obtained from all participants within 3 days of their
arrival in Mexico and at the time of departure. All samples were transported to
the laboratories of the University of Texas Health Science Center at Houston
and stored at 80°C until being tested.
Participants reported to the clinic daily and completed a weekly diary indicat-
ing the number and consistency of bowel movements and the presence of ab-
dominal symptoms, including abdominal pain, excess gas/bloating, nausea, vom-
iting, urgency, tenesmus, and fever. Appropriate treatment for TD was provided.
The study was approved by the committee for the protection of human subjects
of the University of Texas Health Science Center at Houston.
Definitions. Acute diarrhea was defined as the passage of three or more
unformed stools within a 24-h period plus 1 or more abdominal symptoms of
enteric infection. Seroconversion was defined as a fourfold or greater increase in
cholera toxin (CT) antibody titers between the arrival and the departure serum
samples.
Anti-CT antibody test. Each serum sample was evaluated for the presence of
anti-Vibrio cholerae CT B-subunit immunoglobulin G antibodies by enzyme-
linked immunosorbent assay (ELISA). The diluent for both the sera and the
detecting antibody conjugate consisted of phosphate-buffered saline (PBS; 0.01
M, pH 7.2) with 1% skimmed milk. The ELISA washing buffer consisted of PBS
with 0.1% polyoxyethylene-sorbitan monolaureate (Tween 20). Microtiter wells
(Nunc flat 96 Immulon plates; Thermo, Waltham, MA) were coated with 100 l
of purified Vibrio cholerae CT B-subunit (5 g/ml; Sigma Chemical Co., St. Louis,
MO) in sodium bicarbonate buffer (0.1 M, pH 9.0) and incubated overnight at
4°C. The wells were then washed three times using an automated washer (Elx50;
BioTek, Winooski, VT), blocked with 5% skim milk in PBS, and incubated for
1 h at 37°C. After a washing step, twofold serial dilutions of sera were added to
the appropriate wells and incubated for 1 h at 37°C. After an additional washing
step, horseradish peroxidase-conjugated anti-human immunoglobulin G (Sigma
Chemical Co., St. Louis, MO) was added to the wells and incubated for 1 h at
37°C. The washing procedure was repeated, and O-phenylenediamine–H2O2
(Sigma Chemical Co., St. Louis, MO) was added to each well and incubated for
an additional 30 min in the dark at room temperature. The reaction was stopped
by adding 50 l of sulfuric acid (2.5 M) to each well. The color intensity was read
at the 492-nm wavelength with a microplate reader. The end-point antibody titer
was considered to be the highest dilution of the sample that gave an optical
density that was higher than the mean value of the optical density of the standard
negative control plus 2 times the standard deviation (SD).
An interplate control using a standard high-titer control sample was main-
tained, keeping every plate within 2 SDs of the optical density reading. The
antibody titer dilution range to be tested was determined by measuring the
quartile distribution in the first 100 samples.
Genotyping by PCR and pyrosequencing. DNA from participants was ex-
tracted by using a PureGene DNA isolation protocol (Gentra Systems) per the
manufacturer’s instructions. The presence of SNPs in the IL-10 promoter gene
regions (positions 592, 819, and 1082) was determined by using pyrose-
quencing methods. SNP information for the human IL-10 gene was obtained
from the National Center for Biotechnology Information (NCBI) database. The
sequencing primers for SNP genotyping were designed by using SNP Primer
Design software (Biotage AB, Sweden). The probe sequences used were as
follows (critical SNPs are in bold and underlined): for promoter position 1082,
we used TTCTTTGGGAG/AGGGGAAGTA; in the case of the promoter SNP
localized in position 819, we used GGTGATGTAAC/TATCTCTGTG; and in
the case of the SNP in the 592 position, we used CCCCGCCTGTC/ACTGT
AGGAA. For the pyrosequencing step, biotin-labeled PCR fragments were
generated by using a published protocol with 5-GACTGGCTTCCTACAG as
the pyrosequencing primer (28). Biotin-labeled DNA fragments were then cap-
tured on streptavidin-coated magnetic beads (Dynabeads M280; Dynal AS, Oslo,
Norway). The pyrosequencing reactions were performed by using a pyrose-
quencer with a PSQTM 96 SNP reagent kit (Biotage AB, Sweden).
Microbiology examination. In cases of diarrhea, a stool sample was collected
and transported in coolers containing ice to the laboratory. Stool specimens were
subjected to microbiologic analysis in a field laboratory in Mexico. Five individ-
ual E. coli-like colonies were stored in peptone, and an aliquot of stool from each
subject was immediately stored at 20°C until processed. Stool samples were
examined for enteric protozoal parasites, including Giardia lamblia, Entamoeba
histolytica, and Cryptosporidium species, by use of a commercial enzyme immu-
noassay (Alexon, Sunnyvale, CA). Cultures for enteric bacteria were completed
by using six standard media: MacConkey, Tergitol, Hektoen enteric, Yersinia,
thiosulfate-citrate-bile salts-sucrose, and Campylobacter agar plates. The pres-
ence of diarrheagenic E. coli (ETEC, enteroaggregative Escherichia coli [EAEC],
enteropathogenic E. coli [EPEC], enterohemorrhagic E. coli [EHEC], and en-
teroinvasive E. coli [EIEC]) was detected by performing PCR directly from stools
using specific probes (14a). Stools were evaluated for the presence of mucus,
fecal leukocytes, and occult blood by conventional methods.
Statistical analysis. Calculations were done by using SPSS version 14.0 and
NCSS 2007 software. Differences in group characteristics were analyzed by the
Pearson chi-square and Fisher’s exact test (for cells with less than five elements).
Linear variables were compared by using Student’s t test, and geometric variables
were compared by means of the Wilcoxon rank sum test. A multiple logistic
regression model was used for the analysis of risk factors and TD. Significance
was set at a value of 0.05 for subsequent entry into a forward stepwise Wald
regression, with adjustment for each independent variable.
RESULTS
Six hundred forty-two students were enrolled in the study
over 2 years. Seventy-three subjects (11.4%) were lost to fol-
low-up; 25 (3.9%) did not provide a departure blood sample,
and 48 (7.5%) did not come back to the clinic for follow-up.
Thus, a total of 569 participants completed the study. As shown
in Table 1, 403 students were female (70.8%), 516 were Cau-
casian (90.6%), and 57 were of Hispanic ethnicity (10.1%); the
mean age at arrival was 35 years (SD, 14.4), and the mean
length of stay in Mexico was 20 days (SD, 8.3). Two hundred
fifty-five (44.8%) participants developed diarrhea while in
Mexico. There were no significant differences in rates of diar-
rhea related to gender, race, or ethnicity; however, participants
who developed diarrhea were younger (33 versus 36 years; P,
0.01) and stayed longer in Mexico (21 versus 19 days; P, 0.02)
than those who remained asymptomatic during their trip.
Those individuals who developed diarrhea while in Mexico had
lower LT antibody geometric mean titers on arrival, although
the difference was not statistically significant (28.75 versus
20.55; P, 0.07). One hundred twenty-one (21%) participants
had a fourfold increase in LT-specific titers after their stay in
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Mexico, and travelers who developed diarrhea were more
likely to seroconvert than subjects who remained healthy dur-
ing travel (29.4% versus 14.6%; P  0.0001).
Among the 255 participants who developed diarrhea, 173
(67.8%) provided a stool sample for microbiological analysis
when ill. As shown in Table 2, 119 (69%) samples were positive
for diarrheagenic E. coli by means of PCR; ETEC (ST or LT)
was identified in 60 (35%) cases, EAEC was identified in 68
(39%) cases, 12 (7%) cases were found to be positive for
EIEC, 49 (28%) cases were positive for EPEC, and EHEC was
found in 24 (14%) cases. Other bacterial pathogens found by
means of stool culture included five (3%) cases with Salmo-
nella sp. and one (1%) case with Plesiomonas sp. All samples
were negative for Campylobacter or Shigella. Parasites were
found by ELISA in 2.9% of the travelers; three (2%) had
Cryptosporidium sp. and two (1%) had Giardia sp. None of the
samples tested positive for Entamoeba histolytica.
In terms of seroconversion, we observed that ETEC was
more likely to be identified in the stools of travelers who
seroconverted (53% versus 27%; P, 0.001), particularly when
ETEC LT (29% versus 10%; P, 0.003) or ETEC LT/ST (20%
versus 10%; P, 0.056) was found in the stools.
We then analyzed the effect that SNPs in IL-10 alleles had
on diarrhea among ETEC LT seroconverters. As shown in
Table 3, the relative risk (RR) for the development of TD was
significantly higher in subjects with any of the alleles associated
with high levels of IL-10 production. Participants possessing
the 1082 G allele had a 1.24-fold increased risk of developing
TD compared to those with the allele associated with low IL-10
production (95% confidence interval [CI], 1.02 to 1.51; P,
0.03). Participants with the 819 C allele had a 1.53-fold in-
creased risk of TD (95% CI, 1.19 to 1.97; P  0.0001), and
participants with the 592 C allele had a 1.44-fold increased
risk for TD (95% CI, 1.12 to 1.84; P, 0.004).
An analysis of the effect that SNPs in IL-10 haplotypes had
on the risk of acquiring symptomatic diarrhea in subjects who
seroconverted to ETEC LT is shown in Table 4. Participants
with the high-IL-10 GCC haplotype had a significant higher
risk for developing TD (71 versus 57%, RR, 1.85; 95% CI, 1.08
to 3.17; P, 0.02) than those with the ATA haplotype.
In order to determine the relative contribution of the SNPs
to diarrhea in the seroconverter group and to exclude con-
founding variables, we performed a multiple logistic regression
analysis. The independent variables included in the model con-
sisted of factors known to influence susceptibility to TD, such
as gender, ethnicity, race, age on arrival, length of stay, and the
three SNPs of the haplotype associated with a high, interme-
diate, or low level of IL-10 production. In this model, TD was
considered the dependent variable. In the results of this mul-
tivariate analysis, the odds of having TD were significantly
higher for participants having one of the SNPs associated with
high IL-10 production (819 C/C) (odds ratio, 6.8; P, 0.009).
DISCUSSION
Controversy exists around the pathogenic role that ETEC
LT has as an agent of diarrhea. The results of several case-
controlled studies have demonstrated similar rates of infection
in cases and controls. However, most studies have been con-
ducted in areas where ETEC is endemic; in our study of U.S.
travelers with little previous exposure to ETEC LT, we found
a correlation between seroconversion and diarrheal disease. It
is of interest that in this study, a relationship was found be-
tween symptomatic ETEC LT and IL-10 alleles associated with
high IL-10 production. Since LT is both antigenic and immu-
nomodulatory at mucosal surfaces (9), we hypothesize that our
observations could be related to the immunomodulatory prop-
erties of this molecule. LT is composed of two subunits, the
enzymatically active A subunit and the B subunit. The B sub-
unit binds to GM1 ganglioside on the surface of mammalian
TABLE 1. Demographic characteristics of U.S. students
participating in a prospective study of the occurrence
of diarrhea during short-term stay in Mexico
Characteristic
Students
healthy during
travel
(n  314)
TD cases
(n  255) P
a
Gender no. (%) of subjects
Male 90 (54.2) 76 (45.8) 0.8
Female 224 (55.6) 179 (44.4)
Race no. (%) of subjects
White 283 (54.8) 233 (45.2) 0.5
African American 21 (56.8) 16 (43.2) 0.8
Asianb 7 (77.8) 2 (22.2) 0.3
Indian Americanb 1 (50) 1 (50) 0.6
Pacific Islanderb 1 (100) 0 (0) 0.9
Otherb 1 (25) 3 (75) 0.5
Ethnicity no. (%) of
subjects
Non-Hispanic 279 (54.5) 233 (45.5) 0.3
Hispanic 35 (61.4) 22 (38.6)
Agec (yr; mean 	 SD) 36 	 14.6 33 	 13.9 0.01
Length of stayc (days;
mean 	 SD)
19 	 8.1 21 	 8.4 0.02
Geometric mean titer of LT
on arrivald
28.75 20.55 0.07
LT seroconversion 46 (14.6) 75 (29.4) 0.0001
a Comparison of TD case data to healthy control data.
b Fisher’s exact test was used to compare the data for healthy subjects to the
data for TD cases for this group.
c By Student’s t test.
d By Wilcoxon rank sum test.
TABLE 2. Etiology of TD and seroconversion to ETEC LT in U.S.
travelers to Mexico
Pathogen
No. (%) of subjects with indicated status
PbTD
(n  173)
No
seroconversion
(n  124)
Seroconversiona
(n  49)
Diarrheagenic E. coli 119 (69) 86 (69) 33 (67) 0.8
ETEC 60 (35) 34 (27) 26 (53) 0.001
ETEC LT 27 (16) 13 (10) 14 (29) 0.003
ETEC ST 11 (6) 9 (7) 2 (4) 0.4
ETEC LT/ST 22 (13) 12 (10) 10 (20) 0.056
EAEC 68 (39) 52 (42) 16 (32) 0.3
EIEC 12 (7) 9 (7) 3 (6) 0.8
EPEC 49 (28) 36 (29) 13 (26) 0.7
EHEC 24 (14) 17 (14) 7 (14) 0.9
Salmonella spp. 5 (3) 4 (3) 1 (2) 0.7
Shigella spp. 0 (0) 0 (0) 0 (0)
Campylobacter spp. 0 (0) 0 (0) 0 (0)
Plesiomonas spp. 1 (1) 1 (1) 0 (0) 0.5
Cryptosporidium spp. 3 (2) 2 (2) 1 (2) 0.8
Giardia lamblia 2 (1) 2 (2) 0 (0) 0.4
Entamoeba histolytica 0 (0) 0 (0) 0 (0)
No pathogen identified 51 (29) 35 (28) 16 (32) 0.6
a Fourfold rise in antibodies to ETEC LT.
b Comparison of seroconverter data to nonseroconverter data.
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cells and allows for the introduction of the A subunit into the
host cell. The A subunit in turn initiates a cascade of events
that result in watery diarrhea. However, once the B subunit
binds to GM1, a separate series of events takes place which
leads to the transcription of genes involved in modulating the
host inflammatory responses. LT suppresses lipopolysaccha-
ride and gamma interferon-induced tumor necrosis factor al-
pha and IL-12 production but enhances IL-10 secretion by
macrophages (19). Dose-dependent stimulation of IL-10, IL-6,
and tumor necrosis factor alpha by the binding of LT to GM1
receptors has also been demonstrated, causing a downregula-
tion in the Th1 response and a shift toward a Th2 response
(24). It is plausible that during the initial stages of infection,
ETEC LT uses its ability to induce an IL-10-mediated anti-
inflammatory state to limit its own clearance by the host prior
to the formation of effective neutralizing antibodies. In this
context, subjects who are genetically predisposed to produce
high levels of IL-10 would be more likely to experience symp-
tomatic ETEC LT diarrhea that is watery and noninflamma-
tory, and subjects with low IL-10 would mount an inflamma-
tory response that would contain infection early on or result in
rapid clearance of the enteropathogen. Future analysis of
stools for fecal markers of inflammation and cytokines in the
context of IL-10 SNPs may assist in further elucidating the role
that the high-IL-10 genotypes have in ETEC LT-associated
diarrhea.
Our findings also contrast with data from the IL-10-knock-
out mouse studies, in which a chronic enterocolitis mimicking
inflammatory bowel disease occurs after exposure to bacteria.
It is thought that IL-10/ mice are susceptible to continued
inflammation as a result of interactions with endogenous gut
bacteria at the bowel wall (2) and that in the absence of IL-10
there is an unchecked proinflammatory response to luminal
organisms. There is evidence to suggest that this heightened
inflammatory response may be pathogen specific, as demon-
strated by the variable phenotypes of enterocolitis that IL-
10/ mice experience when challenged with different com-
mensal bacteria. Kim et al. have found that severe enterocolitis
can be induced with Enterococcus faecalis, while milder entero-
colitis is seen with E. coli, and no inflammation is caused in the
mice challenged with Pseudomonas fluorescens or those that
are germ free (12). Also as a contrast to the results in this
report, we have previously shown that subjects with a height-
ened proinflammatory state by virtue of polymorphisms in the
IL-8 gene promoter that result in high IL-8 levels in the gut
experience TD due to EAEC, an organism that is more likely
to be associated with intestinal inflammation than ETEC LT
(10). The association of high IL-10 with ETEC LT and high
IL-8 with EAEC suggests that distinct pathways are involved in
host responses to diverse enteropathogens.
This study has several limitations. First, not all travelers with
diarrhea provided a stool specimen. We also found a high
frequency of coinfections with bacterial agents. These con-
founders may limit the power to correlate the relationships of
the different genotypes with individual agents of diarrhea. Sec-
ond, the study design did not include a control group that could
be monitored for asymptomatic colonization to further confirm
the association of the genotypes producing low levels of IL-10
with the pathogens of diarrhea. Third, the exposure to agents
of diarrhea may have not been uniform, as travelers demon-
strate variable degrees of adherence to the avoidance of risky
food items. The microbiologic assessment of all food items
consumed by travelers would have been impractical and cost
prohibitive. Finally, the contribution that this polymorphism
makes to the risk of bacterial diarrhea in travelers is modest,
with a 1.2- to 1.4-fold increase in the likelihood of diarrheal
illness as a whole. It is likely that in addition to unidentified
environmental and immune factors, other genes contribute to
the risk of acquiring TD.
LT has been shown to modulate the mucosal immune re-
sponse in part by enhancing IL-10 production, and this may
explain why individuals genetically predisposed to produce
higher levels of IL-10 are more likely to experience diarrhea
when exposed to ETEC LT. This observation could have im-
portant future applications, such as for determining which in-
dividuals are more likely to become ill with TD, and may prove
a useful tool for targeted prophylaxis of susceptible travelers.
Further understanding of ETEC LT as an immune modulator
TABLE 3. Analysis of alleles of subjects with and without TD among subjects showing seroconversion to ETEC LT
IL-10 gene
position Status of subjects
High IL-10 producers Low IL-10 producers
RR (95% CI) PNo. with
allele %
No. with
allele %
1082 G A
No diarrhea 32 30 60 44 0.03
TD 73 70 77 56 1.24 (1.02–1.51)
819 C T
No diarrhea 57 32 35 56 0.0001
TD 122 68 28 44 1.53 (1.19–1.97)
592 C A
No diarrhea 59 33 33 53 0.004
TD 121 67 29 47 1.44 (1.12–1.84)
TABLE 4. Influence of host IL-10 haplotype on TD occurrence in
U.S. travelers to Mexico
Status of
subjects
No. (%) of subjects witha:
High-IL-10 GCC
haplotype
Intermediate-IL-10
ACC haplotype
Low-IL-10 ATA
haplotype
No diarrhea 18 (29) 20 (43) 8 (62)
TD 44 (71) 26 (57) 5 (38)
a For high (GCC) versus low (ATA) IL-10 haplotypes, the RR is 1.85 (95% CI,
1.08–3.17) (P  0.02).
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and its relationship to the various IL-10 genotypes could also
have important ramifications for vaccine trials.
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